KLRA Kailera Therapeutics, Inc.
$12.80+1.75%
Last close: · regular session · Last 47 sessions
After-hours $12.74 -0.47% ·
- Float
- 91.0M
- Last filing
- 10-Q · Nov 4, 2026
Latest SEC filings for KLRA
| 10-Q | Quarterly report | |
| 3 | ||
| SCHEDULE 13G | ||
| SCHEDULE 13G | ||
| 10-Q | Quarterly report | |
| 8-K | Current report | |
| SCHEDULE 13G | ||
| 3 | ||
| 10-Q | Quarterly report | |
| 8-K | Current report |
Dilution today: new offering filings and reverse splits
Float: 91.0M shares. Latest SEC filing: 10-Q on Nov 4, 2026. KLRA closed at $12.80 (+1.75%) on Nov 4, 2026.
Opening the full analysis uses 1 of your 3 free tickers today.
Chart, dilution, float and news for KLRA in the TickerWise workspace.
Company profile
- Sector: Healthcare
- Industry: Biotechnology
- Country: US
- Exchange: NASDAQ
- Employees: 145
Kailera Therapeutics is a clinical-stage biopharmaceutical company developing a diverse pipeline of next-generation therapies designed to treat obesity and related conditions. The company emphasizes innovative approaches, including injectable and oral formulations, to support chronic weight management. [2] Its lead program is a dual-action gut hormone receptor agonist that has demonstrated promising clinical results in early trials.
Latest KLRA news
- Kailera Therapeutics reports Q3 results Read article
Recent dilution filers
Related companies
Opening the full analysis uses 1 of your 3 free tickers today.
Educational tool only — not investment advice.